TG Therapeutics to Join Jefferies Global Healthcare Conference

Michael S. Weiss, Chairman and CEO of TG Therapeutics, Inc. (NASDAQ: TGTX), is set to participate in the Jefferies Global Healthcare Conference. This event will take place at the Marriott Marquis in New York City on June 5-6, 2024. Weiss will be engaging in a fireside chat on Wednesday, June 5, 2024, at 1:30 PM ET. The discussion will be streamed live on the Events page within the Investors & Media section of the TG Therapeutics website.

TG Therapeutics is a prominent biopharmaceutical company that focuses on the development, acquisition, and commercialization of innovative treatments for B-cell diseases. The company has a robust research pipeline, which includes several investigational therapies. Notably, TG Therapeutics has achieved significant milestones with the FDA's approval of BRIUMVI® (ublituximab-xiiy). This medication is indicated for adults with relapsing forms of multiple sclerosis (RMS), covering clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Additionally, BRIUMVI has received endorsements from the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for treating adults with RMS who exhibit active disease defined by clinical or imaging features in Europe and the United Kingdom.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!